AI-generated analysis. Always verify with the original filing.
RenovoRx, Inc. released full year 2025 financial results, key clinical and commercial updates, and details of its recent $10M financing to support upcoming milestones.
Event Type
Disclosure
Mandatory
Variant
8-K
| Results of Operations and Financial Condition. | |---|---| On March 30, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial r
| Other Events. | |---|---| In addition to announcing certain financial results, the Company’s press release provides certain updates of the Company’s clinical
| Financial Statements and Exhibits. | |---|---| (d) Exhibits | Exhibit No. | | Description | |---|---|---| | | | | | 99.1 | | Press Release of RenovoRx, Inc.,
| Metric | Value | Basis |
|---|---|---|
| Revenue | $1.12 | GAAP |
| Gross Profit | $0.80 | GAAP |
| Research and Development Expenses | $6.27 | GAAP |
| Selling, General and Administrative Expenses | $7.04 | GAAP |
| Net Loss | $-11.17 | GAAP |
| Basic and Diluted EPS | $-0.32 | GAAP |
Mark Voll
Effective: 2026-02
to support commercial growth of RenovoCath